BR9306345A - Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune - Google Patents

Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune

Info

Publication number
BR9306345A
BR9306345A BR9306345A BR9306345A BR9306345A BR 9306345 A BR9306345 A BR 9306345A BR 9306345 A BR9306345 A BR 9306345A BR 9306345 A BR9306345 A BR 9306345A BR 9306345 A BR9306345 A BR 9306345A
Authority
BR
Brazil
Prior art keywords
mammal
suppressing
proliferate
cells
ability
Prior art date
Application number
BR9306345A
Other languages
English (en)
Inventor
David Allen Hafler
Howard M Weiner
Charles B Carpenter
Zhengi Zhang
Mohamed Sayegh
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of BR9306345A publication Critical patent/BR9306345A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
BR9306345A 1992-04-20 1993-04-20 Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune BR9306345A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87128992A 1992-04-20 1992-04-20
US96177992A 1992-10-15 1992-10-15
US97773792A 1992-11-13 1992-11-13
US08/027,127 US5593698A (en) 1990-10-31 1993-03-05 Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
PCT/US1993/003708 WO1993020842A1 (en) 1992-04-20 1993-04-20 Suppression of proliferative response and induction of tolerance with polymorphic class ii mhc allopeptides

Publications (1)

Publication Number Publication Date
BR9306345A true BR9306345A (pt) 1998-06-30

Family

ID=27487557

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9306345A BR9306345A (pt) 1992-04-20 1993-04-20 Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune

Country Status (13)

Country Link
US (1) US5593698A (pt)
EP (1) EP0637249B1 (pt)
JP (1) JPH07505892A (pt)
KR (1) KR100275656B1 (pt)
AT (1) ATE205400T1 (pt)
AU (1) AU686101B2 (pt)
BR (1) BR9306345A (pt)
CA (1) CA2118502A1 (pt)
DE (1) DE69330752D1 (pt)
HU (1) HUT71310A (pt)
IL (1) IL105472A (pt)
NO (1) NO943967D0 (pt)
WO (1) WO1993020842A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6156306A (en) * 1994-08-17 2000-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pancreatic β-cells for allogeneic transplantation without immunosuppression
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
AU2001245848A1 (en) * 2000-03-15 2001-10-23 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
US7348005B2 (en) * 2000-03-15 2008-03-25 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
AU2001264813B2 (en) 2000-05-24 2005-12-08 The United States Of America, As Represented By Secretary Of The Department Of Health And Human Services Methods for preventing strokes by inducing tolerance to e-selectin
HU229377B1 (hu) * 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
CN101820907B (zh) 2007-08-15 2013-05-01 切尔卡西亚有限公司 针对过敏原去敏化的肽
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
US10137181B2 (en) * 2014-04-01 2018-11-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated donor MHC-derived peptide and uses thereof
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
KR102410778B1 (ko) 2016-05-13 2022-06-21 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364762A (en) * 1990-03-21 1994-11-15 Board Of Trustees Of The Leland Stanford Junior University Major histocompatibility complex (MHC) molecules

Also Published As

Publication number Publication date
KR100275656B1 (ko) 2000-12-15
EP0637249A4 (en) 1997-01-08
DE69330752D1 (de) 2001-10-18
ATE205400T1 (de) 2001-09-15
AU686101B2 (en) 1998-02-05
KR950701228A (ko) 1995-03-23
US5593698A (en) 1997-01-14
WO1993020842A1 (en) 1993-10-28
HUT71310A (en) 1995-11-28
JPH07505892A (ja) 1995-06-29
EP0637249B1 (en) 2001-09-12
HU9403006D0 (en) 1994-12-28
CA2118502A1 (en) 1993-10-28
NO943967L (no) 1994-10-19
IL105472A (en) 1999-06-20
EP0637249A1 (en) 1995-02-08
AU4108393A (en) 1993-11-18
NO943967D0 (no) 1994-10-19
IL105472A0 (en) 1993-08-18

Similar Documents

Publication Publication Date Title
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
Hess et al. Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF.
Selby et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation
PT735893E (pt) Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
CA2093513A1 (en) Methods and compositions for suppressing allograft rejection in mammals
MD970009A (en) Methods for inducing T cells tolerance to donor tissues or organs
ES2087163T3 (es) Preparacion antitumoral que comprende intreleucina-2 e histamina, analogo al de las mismas o agonistas de receptor h2.
DE3854300T2 (de) Lymphocyteninhibierung durch hla-peptide.
RU93058532A (ru) Фармацевтическая композиция для остеоиндукции, способ генерации новой кости
GR3027668T3 (en) Immunosuppressive compositions
Otsuka et al. Nicotinamide and 3-aminobenzamide reduce interferon-γ-induced class II MHC (HLA-DR and-DP) molecule expression on cultured human endothelial cells and fibroblasts
AR002005A1 (es) Fragmentos de anticuerpos monoclonales que tienen actividad inmuno supresora, procedimiento para su preparacion, composicion farmaceutica que loscontiene y metodo para la supresion de la respuesta inmune.
NZ234451A (en) Benzofuran-substituted 2-imidazoline derivatives and pharmaceutical compositions
MAckIE et al. Dose-related mechanisms of immunosuppression mediated by murine anti-CD3 monoclonal antibody in pancreatic islet cell transplantation and delayed-type hypersensitivity
ES2082201T3 (es) Uso de il-4 para mejorar la respuesta inmune a las pruebas de antigenos infecciosos.
HK1021318A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
FI981624A (fi) Koostumukset ja menetelmät Borrelia burgdorferi antigeenien annostelemiseksi
Kurpisz et al. Blast transformation of lymphocytes induced by spermatozoa obtained from spermatocoele
Allan et al. In vivo studies on suppressor lymphocyte activity following administration of Escherichia coli O138 lipopolysaccharide
Schoof Murine Leukocyte proliferation following topical application of tumor promoters and other inflammatory agents

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
FC Decision: refusal